Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant

Hawaii Biotech, Inc., Aiea HI

Investigators

Abstract

The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.